WCN26-3036 LOWER INCIDENCE OF HYPOCALCEMIA IN HEMODIALYSIS PATIENTS RECEIVING EVOCALCET COMPARED WITH ETELCALCETIDE: A MULTICENTER COHORT STUDY (MBD-NEXT)

Read full text Summarise with VIRAT
Authors: Kodai Suzuki, Sayaka Shimizu, Maki Hiratsuka, Hirotaka Komaba, Naohiko Fujii, Takayuki Hamano
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Calcimimetics (CM) lower parathyroid hormone leading to reduced serum calcium (Ca) levels in hemodialysis patients. Comparative data of evocalcet (EVO) with etelcalcetide (ETE) is limited. EVO has a much shorter effective half-life than ETE in hemodialysis patients. We compared the risk of hypocalcemia, subsequent dose reduction or discontinuation of CM, and recovery to normocalcemia across these agents.

Fields of Study & Subjects

Parathyroid Disorders and Treatments Dialysis and Renal Disease Management Renal function and acid-base balance

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
103818–103818
Publication date
25 March 2026
Language
EN